Droperidol v. Olanzapine for the treatment of benign headaches:
 

Overview:  The purpose of this study is to determine the efficacy and side effects of Droperidol v. Olanzapine (Zyprexa) when used as a first line treatment for benign, undifferentiated headaches in ED patients.
 

Primary Endpoints: Patient pain as assessed by VAS

Eligible Patients: Patients between 18 and 85 years of age presenting with headaches that the physician believes to be of benign etiology (not due to SAH, meningitis or other secondary cause). Patients are ineligible if they are pregnant or nursing, are prisoners, are intoxicated, or have allergies to droperidol.
 

Study Design: Prospective observational trial
 

Anticipated Benefits: Possible headache relief
 

Potential Risks: Usual risks of medications
 

Research Associate’s Role: The RA is responsible for identifying, enrolling, and collecting data from eligible patients for this study. RA's must have the PMP physician in charge of the patient verify the inclusion and exclusion criteria prior to enrollment. You will also ask the patient make assessments on two different scales (the Barnes Akathisia Scale and the Global Assessment of Akathisia).
 

Physician’s Role: If patient is willing to participate in the study, the RA will ask you make a final determination on the patient’s eligibility. There are a number of disqualifying criteria for the study that you will be asked to review before ordering Droperidol or Olanzapine for your patient. Medications are to be given IM.
 

Location of Study Packets: Team Center B on the center island. Data sheets, consent forms, and drug protocol for the nurse/PMP are all inside of folder.